Medical Device Growth In Emerging Markets: Lessons From Other Industries

Many other industries underwent a similar globalization process a decade ago and essentially reinvented their approaches for the mid-tier of fast growing economies. We believe medical device MNCs can leverage many components of these strategies. Although each industry has unique dynamics and none are perfect parallels, we have focused on the similarities where we believe significant lessons can be learned.

Emerging markets are widely recognized as one of the most important growth frontiers for medical devices. However, multinational players are still trying to unravel the nature of each market and the exact winning formula for success. To date, most multinational companies (MNCs) have focused on the premium customer segment with pre-existing products and commercial models, but we believe the next wave of growth will be in the largely untapped mid-tier of these markets. Emerging markets are experiencing a rise of their middle class, increased access to care and new feature versus price trade-offs that will require rethinking existing strategies and business models.

Many other industries underwent a similar globalization process a decade ago and essentially reinvented their approaches for the mid-tier of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By 

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By 

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By 

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By 

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.